Repros Therapeutics (RPRX) 2.00 $RPRX Repros Presents

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 5:18 PM

Repros Therapeutics (RPRX) 2.00 $RPRX

Repros Presents 6-Month Interim Data on Enclomiphene
Arpita Dutt - Zacks Investment Research - Tue Aug 16, 9:39AM CDT
Repros (RPRX) is developing enclomiphene for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), RPRX: 2.00 (unch), ANIK: 47.89 (-0.05)

Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Wed Aug 10, 6:38AM CDT
Considering that Repros (RPRX) has no approved product in its portfolio at the moment, investor focus will remain on pipeline updates and cash burn.
CBM: 43.27 (+0.10), GERN: 2.75 (+0.02), INCY: 82.02 (+1.21), RPRX: 2.00 (unch)

Repros Therapeutics Inc.(R) Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 9:16AM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2016.
RPRX: 2.00 (unch)

Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Thu Aug 04, 7:45AM CDT
With Repros being a development-stage company, investors will remain focused on the company's pipeline and cash burn.
IPXL: 24.03 (+0.09), INCY: 82.02 (+1.21), RPRX: 2.00 (unch), IONS: 29.46 (-0.58)

Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
GlobeNewswire - Wed Jun 01, 3:01PM CDT
-- EU submission on track with anticipated registration decision expected Fall 2017
RPRX: 2.00 (unch)

Repros Reports Positive Clinical Data for Oral Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Wed May 18, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for the pooled oral doses compared to placebo, p=0.0004
RPRX: 2.00 (unch)

Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board
GlobeNewswire - Mon May 16, 3:00PM CDT
Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.
INSY: 14.63 (+0.27), RPRX: 2.00 (unch)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 36.56 (-0.99), ARQL: 1.40 (unch), APRI: 0.33 (-0.01), RPRX: 2.00 (unch)

Repros Therapeutics reports 1Q loss
Automated Insights - Tue May 10, 8:19AM CDT
WOODLANDS, Texas (AP) _ Repros Therapeutics Inc. (RPRX) on Tuesday reported a loss of $4.8 million in its first quarter.
RPRX: 2.00 (unch)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 42.09 (-0.21), BIIB: 313.59 (+7.56), CNAT: 1.84 (-0.02), AMGN: 169.77 (-0.36), RPRX: 2.00 (unch), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GWPH: 82.73 (+0.45), GERN: 2.75 (+0.02), AVEO: 0.90 (-0.01), ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), NVS: 79.38 (+1.11)

Will Repros Therapeutics (RPRX) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:56AM CDT
As of late, it has definitely been a great time to be an investor in Repros Therapeutics Inc. (RPRX).
RPRX: 2.00 (unch)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (unch), SGYP: 4.77 (+0.01), HRTX: 17.70 (-0.63), RPRX: 2.00 (unch)

Trending Stocks: Investors Have Found Interest In These Four Nasdaq Stocks on Monday
ACCESSWIRE - Mon Apr 18, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 18, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. RPRX, COOL, CLMT, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
UNXL: 1.48 (unch), COOL: 3.70 (-0.05), RPRX: 2.00 (unch), CLMT: 5.47 (-0.04)

Trending Stocks: Thursday's Top Trading Stock Investors Have Followed
ACCESSWIRE - Thu Apr 14, 11:07AM CDT
MIAMI, FL / ACCESSWIRE / April 14, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. COOL, SUNE, RPRX, and EXXI have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
EXXI: 0.13 (-0.01), COOL: 3.70 (-0.05), SUNE: 0.34 (unch), RPRX: 2.00 (unch)

4 Small Cap Stocks That Have To Be On Your Watchlist Today
ACCESSWIRE - Thu Apr 14, 7:30AM CDT
NEW YORK, NY / ACCESSWIRE / April 14, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, CLDX and FNJN are on high volume alert. We have been following RPRX and FELP all week this week. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CLDX: 3.35 (-0.01), RPRX: 2.00 (unch), FNJN: 1.60 (-0.02), FELP: 4.57 (+0.17)

Repros Therapeutics (RPRX) Announces Significant Data for Proellex Phase 2 Meeting with the FDA to Jointly Discuss Plans for Phase 3
ACCESSWIRE - Wed Apr 13, 12:28PM CDT
THE WOODLANDS, TX / ACCESSWIRE / April 13, 2016 / Repros Therapeutics Inc.® (NASDAQ: RPRX) reported that vaginal administration of Proellex at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.
RPRX: 2.00 (unch)

Repros Reveals Positive Data on Proellex for Uterine Fibroids
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 11:30AM CDT
Repros (RPRX) reported positive data from a phase IIb study on Proellex (vaginal administration) for the treatment of women suffering from uterine fibroids.
EBS: 26.90 (+0.49), RPRX: 2.00 (unch), AMAG: 23.66 (-0.05), ANIK: 47.89 (-0.05)

These Small Cap Stocks Are Getting Big Time Attention Today
ACCESSWIRE - Wed Apr 13, 9:50AM CDT
NEW YORK, NY / ACCESSWIRE / April 13, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. RPRX, FELP, EMKR and SUNE are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
EMKR: 5.08 (+0.10), SUNE: 0.34 (unch), RPRX: 2.00 (unch), FELP: 4.57 (+0.17)

Repros Reports Positive Clinical Data for Vaginal Proellex(R) in Women With Severe Menstrual Bleeding Due to Uterine Fibroids
GlobeNewswire - Tue Apr 12, 3:01PM CDT
-- Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011
RPRX: 2.00 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GlycoNex Eyes Japanese Market with Denosumab Biosimilar

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

CureGene's Evategrel Aims for Breakthrough in Stroke Care

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Segway Powersports Ventures into Baja 1000: Ambitions Run High

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Cars.com Inducement Awards: New CPO Earns Stock Boost

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Tencent Cloud's Edge Platform Shines in New Gartner Report

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Cultural Tech Fusion: The Asia-Pacific Way Forward

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...